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Abstract: Skeletal muscle is a major insulin-target tissue and plays an important role in glucose 
homeostasis. Impaired insulin action in muscles leads to insulin resistance and type 2 diabetes 
mellitus. 5′ AMP-activated kinase (AMPK) is an energy sensor, its activation increases glucose 
uptake in skeletal muscle and AMPK activators have been viewed as a targeted approach in 
combating insulin resistance. We previously reported AMPK activation and increased muscle 
glucose uptake by rosemary extract (RE). In the present study, we examined the effects and the 
mechanism of action of rosmarinic acid (RA), a major RE constituent, in L6 rat muscle cells. RA (5.0 
µM) increased glucose uptake (186 ± 4.17% of control, p < 0.001) to levels comparable to maximum 
insulin (204 ± 10.73% of control, p < 0.001) and metformin (202 ± 14.37% of control, p < 0.001). Akt 
phosphorylation was not affected by RA, while AMPK phosphorylation was increased. The RA-
stimulated glucose uptake was inhibited by the AMPK inhibitor compound C and was not affected 
by wortmannin, an inhibitor of phosphoinositide 3-kinase (PI3K). The current study shows an effect 
of RA to increase muscle glucose uptake and AMPK phosphorylation. RA deserves further study as 
it shows potential to be used as an agent to regulate glucose homeostasis. 
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1. Introduction 
Skeletal muscle is a primary target tissue of insulin and plays a critical role in the maintenance 
of glucose homeostasis [1]. After binding to its receptor, insulin increases the receptor tyrosine kinase 
activity which leads to GLUT4 glucose transporter translocation to the plasma membrane via 
activation of the lipid kinase phosphoinositide 3-kinase (PI3K) and the serine/threonine kinase 
Akt/PKB [2,3]. Impairment of the PI3K–Akt cascade leads to insulin resistance and type 2 diabetes 
mellitus (T2DM) [4–6], a disease expected to affect 412 million people globally by 2040 [7]. 
AMP-activated protein kinase (AMPK) is a serine/threonine kinase that has a potential to 
regulate blood glucose levels. As an energy sensor, AMPK is activated by increased AMP/ATP ratio 
and/or via activation of its upstream kinases, liver kinase B1 (LKB1) and calmodulin dependent 
protein kinases (CaMKKs) [8,9]. Muscle AMPK is activated through muscle contraction/exercise [8]. 
Several compounds including metformin [10], thiazolidineones [11] and polyphenols such as 
resveratrol [12] and naringenin [13] are also known to activate AMPK and increase muscle glucose 
uptake. In recent years, AMPK activators have been recognized as a promising pharmacological 
intervention for the prevention and treatment of T2DM [8,9,14–18]. 
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Rosemary (Rosmarinus officinalis L.) is an aromatic evergreen plant endemic to the Mediterranean 
region and South America that is reported to exhibit antioxidant, anticancer and antimicrobial effects 
[19,20]. In addition, beneficial effects have been reported in regards to lipid metabolism and plasma 
glucose levels [21–26]. Previous studies by our group examined the effects of rosemary extract (RE) 
[27] on skeletal muscle cells and found a significant increase in glucose uptake and AMPK activation. 
In vivo studies demonstrated that administration of RE decreased plasma glucose levels in 
streptozotocin-induced diabetic mice [21], rats [23,25,26], alloxan-induced diabetic rabbits [22], and 
in genetic [24] and dietary [26,28,29] animal models of obesity and insulin resistance. RE is composed 
of various polyphenols with carnosic acid (CA) and rosmarinic acid (RA) being the most abundant 
in regards to concentration [30]. It is therefore possible that the beneficial effects observed with RE 
administration may be due to the action of a specific polyphenol. We recently found a significant 
increase in muscle cell glucose uptake and activation of AMPK by CA [31]. 
In the present study, we focused on RA and examined its direct effect on muscle cell glucose 
uptake, and investigated the signaling molecules that may be involved. 
2. Results 
2.1. Rosmarinic Acid (RA) Stimulates Muscle Cell Glucose Uptake 
We reported previously that glucose uptake was significantly increased in L6 muscle cells by 5 
µg/mL of RE [27]. Additionally, previous studies have indicated that RA is one of the major 
constituents found in RE [30], and therefore we examined the levels of RA present in the RE that was 
extracted in our lab and utilized previously [27]. To this end, we performed high-performance liquid 
chromatography (HPLC) and a representative chromatograph is shown in Figure 1A. The retention 
time of the peak which corresponds to RA from the standard was utilized to determine the presence 
of RA in the extract. The area under the peak corresponding to the RA present in the extract was used 
to quantify the relative amount of RA. Our data demonstrate that RE contained 13.39 ± 0.23% RA. 
Based on these values and the molecular weight of RA (MW: 360.13 g/mol), we calculated the 
concentration of RA in media containing 5 µg/mL of RE, a concentration that elicited maximal 
stimulation of glucose uptake in our previous study [27], and found that the corresponding 
concentration of RA is 2.0 µM. We then went on to investigate whether RA at a concentration of 2.0 
µM would have any effect on the glucose uptake. However, we wished to obtain a dose-response 
curve and for this reason we used additional concentrations. 
L6 muscle cells were differentiated in α-Minimal Essential Medium (α-MEM) containing 2% 
(v/v) Fetal bovine serum (FBS), as previously described [12,13,27]. Myotubes were incubated with 0.1, 
0.5, 2, 5 or 10 µM RA for 4 h (Figure 1B). RA at 0.1 and 0.5 µM did not increase glucose uptake (105 ± 
4.80% of control and 114 ± 3.96% of control respectively, both p > 0.05). However, higher concentration 
of RA resulted in a dose-dependent increase in glucose uptake. Significant stimulation of glucose 
uptake was seen at 2 µM RA (127 ± 4.04% of control, p < 0.01), and maximum stimulation was seen at 
5 µM RA (186 ± 7.31% of control, p < 0.001) (Figure 1). It should be noted that higher concentration of 
RA (10 µM) also stimulated glucose uptake (181 ± 7.88% of control, p < 0.001) without any changes in 
cell morphology or cell toxicity assessed by microscopic examination. 
We further investigated if the effect of RA on glucose uptake is time-dependent. Fully 
differentiated myotubes were incubated with 5 µM RA for 0.25, 0.5, 1, 2, 4, 6, 12 or 24 h (Figure 2). 
Significant stimulation was seen after 2 h of RA exposure (126.6 ± 3.32% of control, p < 0.01) while 
maximum stimulation was observed after 4 h of exposure (186 ± 7.38% of control, p < 0.001) (Figure 
2). Longer exposure time of 12 and 24 h to RA also significantly stimulated glucose uptake (166 ± 
4.00% of control and 167 ± 2.00% of control, respectively, both p < 0.001) (Figure 2). 




Figure 1. (A) Levels of rosmarinic acid (RA) present in rosemary extract (RE). High-performance 
liquid chromatography (HPLC) chromatograph representing RE (upper panel) and RA standard 
(lower panel). (B) Effects of rosmarinic acid (RA) on glucose uptake (dose response). Serum-deprived 
L6 myotubes were incubated without or with 0.1, 0.5, 2, 5 or 10 µM RA for 4 h. 2-deoxy-D-glucose 
uptake was measured according to the methods. Data are expressed as percentage of control. Results 
are the mean ± SE of 3–4 independent experiments. ** p < 0.01, *** p < 0.001, vs control. 
 
Figure 2. Effects of rosmarinic acid (RA) on glucose uptake (Time-course). Serum-deprived L6 
myotubes were incubated without or with 5 µM RA for the indicated time. Data are expressed as 
percentage of control. Results are the mean ± SE of 3–5 independent experiments. ** p < 0.01, *** p < 
0.001, vs control. 
We compared the effect of RA with that of insulin and metformin, the most widely 
used/prescribed medication for T2DM. It is important to note that the maximum stimulation of 
glucose uptake seen with RA treatment (186 ± 7.31% of control, p < 0.001) was comparable to the 
response seen with maximum insulin (100 nM, 0.5 h, 204 ± 10.73% of control, p < 0.001) and metformin 
(2 mM, 2 h, 202 ± 14.37% of control, p < 0.001) stimulation (Figure 3A). Exposure of myotubes to 5 
µg/mL of rosemary extract (RE) also significantly increased glucose uptake (197 ± 3.60% of control, p 
< 0.001) in agreement with our previous studies [27,31]. 
2.2. Effect of Rosmarinic Acid (RA) on Insulin-Stimulated Glucose Uptake 
We further investigated the effects of RA on insulin-stimulated glucose uptake. Myotubes were 
exposed to 5.0 µM RA (4 h) followed by treatment with 3 nM (sub-maximal) or 100 nM (maximal) 
insulin. Insulin at submaximal 3 nM concentration increased glucose uptake (I 3 nM: 160 ± 8.34% of 
control); and this response was significantly enhanced by RA treatment (RA + I 3 nM: 214 ± 11.49% 
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of control) (Figure 3B). However, RA did not affect the maximum insulin-stimulated glucose uptake 
(I 100 nM: 205 ± 10.34% of control, RA + I 100 nM: 203 ± 10.17% of control) (Figure 3B). 
 
(A) (B)
Figure 3. (A) Effects of rosmarinic acid (RA), rosemary extract (RE), insulin (I) and metformin (MET) 
on glucose uptake. Serum-deprived L6 myotubes were incubated without (control, C) or with 5 µM 
RA (4 h), 5 µg/mL RE (4 h), 100 nM I (0.5 h) or 2 mM MET (2 h) followed by 2-deoxy-D-glucose uptake 
measurements. Results are the mean ± SE of 5 independent experiments. *** p < 0.001, vs control. (B) 
Effect of rosmarinic acid (RA) on insulin-stimulated glucose uptake. Serum-deprived L6 myotubes 
were incubated without or with 5 µM RA (4 h) followed by stimulation with 3 nM or 100 nM insulin 
for 0.5 h and glucose uptake measurements. Results are the mean ± SE of 3–4 independent 
experiments. *** p < 0.001, vs control, # p < 0.05 vs insulin alone. 
2.3. Effects of Rosmarinic Acid (RA) on AMPK Signaling 
In our previous studies we found significant increase in AMPK phosphorylation by RE [27] and 
carnosic acid [31], and therefore we hypothesize that RA may also increase AMPK phosphorylation. 
Treatment of L6 myotubes with RA resulted in a robust increase in AMPK phosphorylation on 
threonine 172 [32], an indicator of activation (Figure 4A). Importantly, the activation of AMPK seen 
with RA treatment was at the same level as with 2mM metformin treatment (Figure 4A). Treatment 
with RE also increased AMPK phosphorylation (Figure 4A) in agreement with our previous studies 
[27,31]. To examine the involvement of AMPK in glucose uptake, we used the AMPK inhibitor, 
compound C (CC). RA-stimulated glucose uptake was significantly inhibited by CC (RA: 186 ± 4.17% 
of control, CC + RA: 163 ± 8.23% of control) (Figure 4B). RE-stimulated glucose uptake was also 
inhibited by CC (RE: 197 ± 3.60% of control, CC + RE: 135 ± 4.01% of control) (Figure 4B), while the 
metformin-stimulated glucose uptake was abolished in the presence of CC (MET: 202 ± 14.37% of 
control, CC + MET: 103 ± 7.23% of control) (Figure 4B). We also investigated the effect of CC on RA-
stimulated phosphorylation of AMPK (Figure 4C). CC blocked the RA-induced AMPK 
phosphorylation, indicating that the use of a CC inhibitor in our study was effective in blocking 
AMPK (Figure 4C). Additionally, we examined the phosphorylation of the downstream 
physiological target of AMPK, acetyl-CoA carboxylase (ACC). Treatment with RA resulted in 
significant increase in ACC phosphorylation that was completely blocked in the presence of CC 
(Figure 4D), further indicating AMPK activation by RA treatment and effective blocking by CC. 
To examine the involvement of Ca2+/calmodulin-dependent kinase kinase (CaMKK)—an 
upstream regulator of AMPK—in RA-stimulated glucose uptake, we used the CaMKK-selective 
inhibitor STO-609 [33]. Exposure of L6 myotubes to STO-609 (27 µM) did not affect the basal glucose 
uptake (106 ± 2.6% of control) (Figure 5A). Furthermore, the RA-stimulated glucose uptake was not 
affected by STO-609 (RA: 190 ± 4.6% of control, STO + RA: 191 ± 4.7% of control) (Figure 5A). 
Additionally, we investigated the effect of STO-609 on RA-induced phosphorylation of AMPK and 
its downstream effector ACC (Figure 5B,C). Treatment with STO-609 alone did not affect AMPK or 
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ACC phosphorylation. Furthermore, the RA-induced phosphorylation of AMPK and ACC was not 
affected by STO-609 treatment, indicating that CaMKK is not involved in the RA-induced 




Figure 4. (A) Effect of RA on AMPK. L6 myotubes were treated without (control, C) or with 5.0 µM 
RA (2 h), 5 µg/mL of RE (2 h), 2 mM metformin (MET) (2 h). Whole-cell lysates were prepared, 
resolved by SDS-PAGE and immunoblotted with specific antibodies that recognize phospho-AMPK 
(Thr 172) (P-AMPK) or total AMPK (T-AMPK). (B) Effect of compound C (CC) on rosmarinic acid 
(RA)-induced glucose uptake. Cells were incubated in the absence or presence of 25 µM compound 
C (CC) for 30 min followed by the addition of 5.0 µM RA, 5 µg/mL of RE or 2 mM MET and glucose 
uptake measurements. Results are the mean ± SE of 6–7 independent experiments. *** p < 0.001 vs 
control. ### p < 0.001 vs treatment in the absence of CC. (C) Effect of compound C (CC) on RA-induced 
AMPK and (D) ACC phosphorylation. Whole-cell lysates were immunoblotted for phospho-AMPK 






Figure 5. (A) Effect of STO-609 on rosmarinic acid (RA)-induced glucose transport. L6 myotubes were 
incubated in the absence (control, C) or presence of 27 µM STO-609 (STO) for 1 hour followed by the 
addition of 5.0 µM RA (4 h) and glucose uptake measurements. Results are the mean ± SE of 3 
independent experiments. *** p < 0.001 vs control. ### p < 0.001 vs treatment in the absence of STO-609. 
(B) Effect of STO-609 (STO) on AMPK and (C) ACC phosphorylation. Whole-cell lysates were 
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immunoblotted for phospho (Thr 172) (P-AMPK) or total AMPK (T-AMPK) (B) or for phospho (Ser 
79) (P-ACC) or total ACC (T-ACC) (C). 
2.4. Effect of Rosmarinic Acid (RA) on PI3K–Akt Signaling Cascade 
The effects of RA on the PI3K-Akt signaling cascade, the key players involved in insulin-
stimulated glucose uptake, were also examined. For that purpose, we used the PI3K inhibitor 
wortmannin. Wortmannin did not have an effect on RA-stimulated glucose uptake (RA: 186 ± 4.17% 
of control, W + RA: 182 ± 6.32% of control) or RE-stimulated glucose uptake (RE: 202 ± 10.60% of 
control, W + RE: 192 ± 10.42% of control), indicating that the PI3K signaling is not involved (Figure 
6A). On the other hand, wortmannin completely blocked insulin-stimulated glucose uptake (I: 204 ± 
9.10% of control, W + I: 123 ± 8.91% of control), indicating effective blocking of PI3K by wortmannin. 
We further examined the effect of RA on Akt. Our data indicated that RA does not have an effect on 
Akt phosphorylation or expression, contrary to the significant phosphorylation of Akt observed with 
insulin stimulation (Figure 6B). Metformin also did not affect the levels of Akt 
phosphorylation/expression (Figure 6B). In addition, the phosphorylation of the downstream 
physiological target of Akt, p70 S6K, was investigated. Treatment with RA and metformin did not 
affect the phosphorylation/expression of p70 S6K. In contrast, treatment with insulin lead to a robust 
increase in p70 S6K phosphorylation (Figure 6C). Altogether, these data show no effect of RA on the 





Figure 6. (A) Effect of wortmannin (W) on rosmarinic acid (RA)-induced glucose uptake. L6 myotubes 
were incubated in the absence (control, C) or presence of 100 nM wortmannin (W) for 15 min followed 
by the addition of 5.0 µM RA (4 h), 5 µg/mL of RE (4 h) or 100 nM insulin (30 min) and glucose uptake 
measurements. Results are the mean SE of 6–7 independent experiments. *** p < 0.001 vs control.  
### p < 0.001 vs treatment in the absence of wortmannin. (B) and (C) Effect of rosmarinic acid (RA) on 
Akt and P70 S6K phosphorylation. L6 myotubes were treated without (control, C) or with 5.0 µM RA 
(2 h), I 100 nM (30 min) or 2 mM metformin (MET) (2 h). Whole-cell lysates were prepared, resolved 
by SDS-PAGE and immunoblotted with specific antibodies that recognize phosphorylated Akt (P-
Akt) or total Akt (T-Akt) (B) or phosphorylated p70 S6K (P-p70S6K) or total p70 S6K (T-p70S6K) (C). 
2.5. Effect of PKC Inhibition on RA-Stimulated Glucose Uptake 
Previous evidence indicates that activation of protein kinase C (PKC) leads to an increase in 
glucose uptake in muscle cells in response to different stimuli [34–37]. Based on this evidence and 
our data showing partial and not complete inhibition of RA-stimulated glucose uptake with AMPK 
inhibition (Figure 4B), we hypothesized that PKCs may play a role in RA-stimulated glucose uptake. 
To address this hypothesis, we used bisindolylmaleimide I (BMD), a selective inhibitor of PKCα-, βI-
, βII-, γ-, δ- and ε- isozymes, used extensively in other studies [38–40]. BMD did not have any effect 
on the basal glucose uptake (103 ± 3.4% of control) (Figure 7A). Furthermore, RA-stimulated glucose 
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uptake was not affected by BMD (RA: 190 ± 4.6% of control, BMD + RA: 188 ± 7.3% of control) (Figure 
7A). Additionally, we investigated the effect of RA on PKC phosphorylation, which is correlated with 
an increase in PKC activity [41], using a specific antibody phospho-PKC (pan) that recognizes 
conventional (α, βI, βII) and novel (δ, ε, η and θ) PKCs (Figure 7B). Treatment of the cells with RA did 
not have any effect on PKC phosphorylation/activation (Figure 7B). On the other hand, treatment 
with 12-O-tetradecanoylphorbol-13-acetate (TPA) significantly increased PKC phosphorylation. 
Furthermore, in the presence of BMD, the TPA-induced PKC phosphorylation/activation was 
completely abolished, indicating that in our experiments, BMD acts as an effective inhibitor of PKCs. 
 
(A) (B)
Figure 7. (A) Effect of bisindolylmaleimide I (BMD) on rosmarinic acid (RA)-induced glucose 
transport. L6 myotubes were incubated in the absence (control, C) or presence of 1 µM 
bisindolylmaleimide I (BMD) for 1 h followed by the addition of 5.0 µM RA (4 h) and glucose uptake 
measurements. Results are the mean ± SE of 3 independent experiments. *** p < 0.001 vs control.  
### p < 0.001 vs treatment in the absence of BMD. (B) Effect of RA on PKC phosphorylation. Cells were 
incubated in the absence or presence of 1 µM BMD for 1 h followed by addition of 5.0 µM RA (2 h) or 
200 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) (20 min). Whole-cell lysates were prepared, 
resolved by SDS-PAGE and immunoblotted with specific antibodies that recognize 
phosphorylated/activated PKC. 
2.6. Effect of RA on Glucose Transporters 
To elucidate the mechanism by which RA increased glucose uptake, we measured plasma 
membrane GLUT4 and GLUT1 levels in GLUT4myc- and GLUT1myc-overexpressing cells, 
respectively. RA did not cause a significant increase in plasma membrane GLUT4myc levels (117 ± 
2.70% of control, p > 0.05) (Figure 8A). On the other hand, maximal insulin (10−7 M, 20 min) and 
metformin (1 mM for 2 h) treatment stimulated GLUT4myc translocation (207 ± 7.86% of control and 
175 ± 12.47% of control, respectively, both p < 0.001) (Figure 8A). RE did not have any effect on 
GLUT4myc translocation (106 ± 3.20% of control, p > 0.05). Similarly, RA and RE did not cause a 
significant increase in plasma membrane GLUT1myc levels (116 ± 2.51% of control and 113 ± 5.52% 
of control, respectively, both p > 0.05) (Figure 8B). Insulin (10−7 M, 20 min) and metformin (1 mM, 2 
h) significantly increased plasma membrane GLUT1 levels (139 ± 1.44% of control and 135 ± 2.14% of 
control, respectively, both p < 0.001) (Figure 8B). It should be noted that RA increased glucose uptake 
in GLUT4myc (178 ± 8.62% of control, p < 0.01) and GLUT1myc (198 ± 3.84% of control, p < 0.001) 
overexpressing cells (Figure 8C,D). 






Figure 8. Effect of RA on plasma membrane GLUT levels and glucose uptake in GLUT-overexpressing 
cells. L6 GLUT4myc (A,C) or GLUT1myc (B,D) overexpressing cells were treated with 5 µM 
rosmarinic acid (RA) (4 h), 5 µg/mL rosemary extract (RE) (4 h), insulin (I) (100 nM, 0.5 h), or 2 mM 
metformin (MET) (4 h), followed by GLUT4 or GLUT1 plasma membrane transporter level 
measurements (A,B) or glucose uptake measurements (C,D). Results are mean ± SE of 5–7 
independent experiments. *** p < 0.001vs control. 
3. Discussion 
We previously found that treatment of L6 muscle cells with 5 µg/mL of rosemary extract 
increased glucose uptake to a level comparable to maximum stimulation observed with insulin and 
metformin [27], and we hypothesized that specific polyphenols present in the RE may contribute to 
the increase in glucose uptake. We measured the direct effect of carnosic acid on muscle cells and 
found a significant increase in glucose uptake and activation of AMPK [31]. In the current study, we 
continued our investigation and focused on the rosemary polyphenol rosmarinic acid (RA). 
To this end, we conducted high-performance liquid chromatography (HPLC) to measure the 
levels of RA present in our RE, and it was found to be 13.39%. This concentration of RA was 
comparable to previous concentrations reported to be found in RE [42]. Based on the values obtained 
from the HPLC and the molecular weight of RA (MW: 360.32 g/mol), we calculated that in media 
containing 5 µg/mL of our rosemary extract, the corresponding concentration of RA is 2 µM. We 
wished to examine if this micromolar concentration of RA affects muscle glucose uptake. This study 
is the first to demonstrate that RA concentration as low as 2 µM stimulated glucose uptake in L6 
muscle cells to significant levels. Importantly, a stimulation comparable to maximal insulin and 
metformin was observed at 5 µM RA, indicating a potential for RA to be used similar to metformin 
as a pharmacological intervention in the treatment of insulin resistance. 
RA did not affect the maximal (100 nM) but significantly enhanced the submaximal (3 nM) 
insulin response. These data suggest that when the insulin response is reduced (is at submaximal 
levels), as in the case of insulin resistance, treatment with RA has the potential to restore glucose 
uptake and therefore may be beneficial. Future studies should examine the effects of RA on insulin-
resistant muscle cells. 
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In the present study, it was found that the effect of RA on glucose uptake is PI3K-independent, 
since wortmannin, an irreversible inhibitor of PI3K, did not affect the RA-stimulated glucose uptake. 
Wortmannin completely blocked the insulin-stimulated glucose uptake, and therefore, we are 
confident that wortmannin effectively blocked PI3K activation in our studies. Additionally, Akt 
phosphorylation and phosphorylation of its downstream target, p70 S6K, was not affected by RA, 
while a robust activation was seen with insulin treatment. These data clearly indicate activation of 
the PI3K–Akt cascade by insulin without any effect on this cascade by RA. 
Importantly, treatment with RA significantly increased AMPK phosphorylation at its Thr 172 
residue, which correlates highly with kinase activity and is used as a marker of its activation 
[8,9,14,32]. Moreover, treatment with RA significantly increased the phosphorylation of ACC, a 
downstream effector of AMPK, used as an index of AMPK activity in numerous studies [8,9,14,32]. 
Compound C, an ATP-competitive inhibitor of AMPK, significantly decreased the RA-mediated 
glucose uptake, indicating AMPK involvement in the action of RA. Compound C abolished the RA-
stimulated phosphorylation of AMPK and ACC, indicating effective inhibition of AMPK in our 
study.  
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK), an upstream regulator of AMPK, 
phosphorylates Thr172 and increases AMPK activity [43,9,14]. CaMKK may be mediating the 
increase of muscle AMPK activity by a variety of stimuli including contraction [44] and oxytocin [45]. 
We hypothesized that CaMKK may be involved in RA-stimulated glucose uptake, and to address our 
hypothesis we used STO-609, an established inhibitor of CaMKK [33]. Our study showed that 
inhibition of CaMKK by STO-609 did not affect the RA-stimulated glucose uptake or the RA-induced 
AMPK phosphorylation, indicating that this kinase is not involved in the mechanism of action of RA. 
According to Hawley et al., there is a possibility that STO-609 may directly inhibit AMPK activity 
without affecting the phosphorylation of AMPK [46]. Therefore, we examined phosphorylation of 
ACC, the downstream target of AMPK, established as a proxy of AMPK activity. STO-609 did not 
have any effect on the RA-induced phosphorylation of ACC, further indicating that CaMKK is not 
involved in the RA-stimulated glucose uptake. 
It is important to note that the RA-stimulated glucose uptake, although significantly reduced by 
compound C, was not completely abolished. This partial inhibition of RA-stimulated glucose uptake 
under conditions of AMPK inhibition suggests that signaling molecules other than AMPK may be 
involved in the action of RA. Different studies indicate that conventional/novel PKCs may be 
involved in the increase of muscle glucose uptake by different stimuli [47,48,34]. A significant part of 
metformin-stimulated muscle glucose uptake was found to be independent of AMPK and dependent 
on novel /conventional PKCs [34]. We therefore hypothesized that PKCs may be involved in the RA-
stimulated glucose uptake, and to address our hypothesis, we used bisindolylmaleimide I (BMD), a 
selective inhibitor of conventional/novel PKCs widely used in other studies [37,49], and found that 
the RA-stimulated glucose uptake was not affected by BMD. We further performed western blot 
experiments examining phosphorylation/activation of PKCs. We used an antibody that recognizes 
endogenous levels of conventional (α, βI, βII) and novel (δ, ε, η and θ) PKCs phosphorylated at the 
carboxy-terminal residue homologous to Ser 660 of PKCβII (P-PKC). It should be noted that PKC 
phosphorylation at this specific site recognized by the antibody used correlates with increased PKC 
activity [41]. We are confident that PKCs are expressed and can be activated in L6 myotubes, as we 
found a robust phosphorylation/activation of PKC with 12-O-tetradecanoylphorbol-13-acetate (TPA) 
treatment. Importantly, the TPA-induced PKC phosphorylation/activation was completely abolished 
by BMD, indicating that in our studies, BMD was an effective inhibitor of PKCs. Taken together, our 
data indicate that the RA-stimulated glucose uptake is independent of conventional and novel PKCs. 
It is possible that atypical PKCs may be involved in the RA-induced glucose uptake and this could 
be further examined in the future. 
L6 muscle cells express GLUT1, GLUT3 and GLUT4 glucose transporters [50]. We measured 
plasma membrane GLUT1 and GLUT4 levels in L6 cells overexpressing GLUT1 or GLUT4, 
respectively. Our data showed that there was no significant increase in plasma membrane levels of 
GLUT1 or GLUT4 by RA, although there was a significant increase in glucose uptake. RE treatment 
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also did not significantly increase plasma membrane levels of GLUT1 or GLUT4, in agreement with 
our previous studies [27,31]. On the contrary, both insulin and metformin increased GLUT1 and 
GLUT4 plasma membrane levels in agreement with previous studies [27,31,51]. It is possible that the 
increase in glucose uptake by RA in the present study may be due to either GLUT3 translocation 
(since GLUT3 is also expressed in L6 cells [50]) or increased intrinsic activity of the plasma 
membrane-localized GLUTs. A recent study has shown that acute (30 min) treatment with 
triiodothyronine (T3) increased glucose uptake in GLUT4myc-overexpressing L6 muscle cells 
without increasing GLUT4 translocation to the cell membrane [52], suggesting that T3 enhanced the 
activity of the GLUTs present on the cell membrane. The effect of RA is similar to the effect observed 
with RE [27] and CA [31] treatment in our previous studies, and similar to the effect of T3 [52], 
suggesting that these stimuli/treatments may increase the activity of plasma membrane-localized 
GLUTs.  
A limited number of studies performed in cardiomyocytes [53,54] and C2C12 muscle cells [55] 
indicate that RA reduces cellular reactive oxygen species (ROS) levels and has antioxidant properties. 
Antioxidants such as astaxanthin, α-tocopherol and α-lipoic acid [56] have been shown to increase 
glucose uptake in L6 muscle cells, and therefore, it is possible that the increase in glucose uptake seen 
by RA in our study is due to its antioxidant properties. In a recent study, treatment of L6 muscle cells 
with 20 µM RA prevented the palmitate-induced decline of the mitochondria biogenesis markers 
PGC-1a, SIRT-1 and TFAM, an effect that was similar to metformin treatment [57]. In addition, RA 
prevented the palmitate-induced IRS-1 (ser307) phosphorylation and the decline in plasma 
membrane GLUT4 levels [57]. 
A limited number of studies have also examined the antidiabetic effects of RA in vivo. 
Administration of RA (120–200 mg/kg, 7 days) dose-dependently ameliorated hyperglycemia and 
insulin resistance and prevented reduction in GLUT4 expression in streptozotocin (STZ)-induced 
diabetic rats [26]. Furthermore, RA (100 mg/kg bw/day) increased AMPK and modulated the 
expression of mitochondrial biogenesis markers SIRT-1, PGC-1a and TFAM in high-fat-diet STZ-
diabetic rats in addition to restoring GLUT4 levels to the plasma membrane [57]. 
It is important to note that for the first time, the tolerability and safety of RA was recently 
assessed in humans [58]. Healthy volunteers were given Melissa officinalis (lemon balm) extract 
containing 500 mg of RA. The total serum concentration of RA reached maximum (162.20 nM) in 1 h 
after the administration in fasting state [58], clearly indicating that RA is readily absorbed. More 
importantly, administration of the extract containing RA had no effect on the blood, kidney or liver 
function parameters, and no side-effects were reported [58]. Although this study indicates RA is well-
tolerated and safe in humans [58], more studies are required to examine safety and potential toxicity 
of chronic RA administration. 
4. Conclusions 
In conclusion, the present study shows a direct effect of rosmarinic acid (RA) to significantly 
increase glucose uptake in L6 muscle cells to levels comparable to insulin and metformin. The glucose 
uptake was partially but significantly inhibited in the presence of compound C, an inhibitor of 
AMPK, but was not affected by wortmannin, an inhibitor of PI3K, indicating a mechanism that is 
partially dependent on AMPK and independent of PI3K. Overall, more studies should be performed 
to investigate further the potential of rosmarinic acid to be used to prevent and/or manage insulin 
resistance and T2DM. 
5. Materials and Methods 
5.1. Materials 
Fetal bovine serum (FBS), rosmarinic acid, dimethyl sulfoxide (DMSO), o-phenylenediamine 
dihydrochloride (OPD), cytochalasin B and STO-609 inhibitor were purchased from Sigma Life 
Sciences (St. Louis, MO, USA). Materials for cell culture were purchased from GIBCO Life 
Technologies (Burlington, ON, Canada). Several antibodies were used in our study, including 
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phospho- and total-AMPK (CAT 2531 and 2532, respectively, New England BioLabs (NEB) 
(Missisauga, ON, Canada), rabbit, 1:1000 dilution), Akt (CAT 9271 and 9272, New England BioLabs 
(NEB) (Missisauga, ON), rabbit, 1:1000 dilution), ACC (CAT 3661 and 3676, New England BioLabs 
(NEB) (Missisauga, ON), rabbit, 1:1000 dilution), p70 S6K (CAT 9205 and 2708, New England BioLabs 
(NEB) (Missisauga, ON), rabbit, 1:1000 dilution), phospho-PKC (pan) (βII Ser660) (CAT 9371, New 
England BioLabs (NEB) (Missisauga, ON), rabbit, 1:1000 dilution), 12-O-tetradecanoylphorbol-13-
acetate (TPA) (CAT 4174, New England BioLabs (NEB) (Missisauga, ON)) and HRP-conjugated anti-
rabbit antibodies (CAT 7074, New England BioLabs (NEB) (Missisauga, ON), 1:2000 dilution). In 
addition, anti-c-myc antibodies (CAT 3956, Sigma Life Sciences, 1:500 dilution) and peroxidase-
conjugated goat anti-rabbit IgG were purchased from Sigma Life Sciences and Jackson 
ImmunoResearch Labs (West Grove, PA, USA (CAT: 111-035-144, 1:1000 dilution), respectively. 
Insulin (Humulin R) was from Eli Lilly (Indianapolis, IN, USA). Compound C, wortmannin and 
bisindolylmaleimide I were purchased from Calbiochem (Gibbstown, NJ, USA). Luminol Enhancer 
reagents, polyvinylidene difluoride (PVDF) membrane, and reagents for electrophoresis and 
Bradford protein assay were purchased from BioRad (Hercules, CA, USA). [3H]-2-deoxy-D-glucose 
was purchased from PerkinElmer (Boston, MA, USA). 
5.2. Measurement of Rosmarinic Acid Levels in Rosemary Extract 
The preparation of RE was conducted as previously described. As a standard we used RE and 
RA which were dissolved at a concentration of 2 mg/mL in sterile DMSO. 2.5 µL of previously 
prepared aliquots were injected into a reversed-phase Agilent 1100 series high-performance liquid 
chromatography (HPLC) instrument which was equipped with an autosampler. Quantification and 
separation were conducted at 25 °C via mobile phase consisting of solvent A and solvent B. Solvent 
A consisted of 0.1% formic acid and solvent B consisted of acetonitrile. Over 30 min, a linear gradient 
of 95% solvent A and 5% solvent B was attained. The detection was set at 254 nm and the flow rate at 
0.4 mL/min. Identification of RA was achieved by comparison of the actual retention time to those of 
authentic reference standard of RA. Furthermore, quantification of RA was done by calculating the 
peak areas after completion of HPLC separation. Mean total content was expressed in % (g/100 g dry 
weight extract). 
5.3. Cell Culture, Treatment and Glucose Uptake Assay 
L6 rat muscle (parental, overexpressing GLUT4myc and GLUT1myc) cells were grown in α-
MEM media containing 2% v/v fetal bovine serum (FBS) until fully differentiated. Myotube stage was 
reached at approximately 6 to 7 days after seeding. Prior to the experiments, the cells were serum-
deprived for 3 h followed by treatment as described in the figures. After treatment, the cells were 
washed with HEPES-buffered saline (HBS) solution and exposed to 10 µM [3H]-2-deoxy-D-glucose 
in HBS for 10 min to measure glucose uptake. Exposure to 10 µM cytochalasin B was used to 
determine the non-specific glucose uptake. At the end of the 10 min uptake time, the cells were rinsed 
with 0.9% NaCl solution followed by 0.05 M NaOH lysis buffer. Liquid scintillation counter 
(PerkinElmer) was used to measure radioactivity. Bio-Rad protein assay was used to quantify protein 
levels. 
5.4. Immunoblotting 
After treatment, whole lysates were obtained by washing the cells with ice-cold HBS solution 
and lysing with ice-cold lysis buffer. Lysates were kept at −20 °C. Protein samples (15 µg) were 
separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to PVDF membrane followed by exposure to blocking buffer containing 5% w/v dry milk 
powder in Tris-buffered saline and overnight incubation with the primary antibody at 4 °C followed 
by exposure to HRP-conjugated anti-rabbit antibody for 1 h and Luminol Enhancer reagents 
(BioRad). The corresponding bands were visualized using FluroChem software (ThermoFisher, 
Waltham, MA, USA). 
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5.5. GLUT4myc and GLUT1myc Translocation Assay 
After treatment, fully differentiated GLUT4myc- or GLUT1myc-overexpressing myotubes were 
fixed using 3% paraformaldehyde for 10 min at 4 °C and additional 20 min at room temperature 
followed by exposure to 1% glycine in PBS, and blocked with 10% goat serum in PBS for 15 min at 4 
°C. The cells were then incubated with an anti-myc antibody for 60 min at 4 °C followed by exposure 
to peroxidase-conjugated goat anti-rabbit IgG at room temperature for 30 min. The cells were rinsed 
and incubated with o-phenylenediamine dihydrochloride (OPD) reagent for 30 min at room 
temperature and the reaction was stopped by adding 3 M HCl. The absorbance of the supernatant 
was measured at 492 nM. 
5.6. Statistical Analysis 
GraphPad Prism v7.0 (GraphPad Software, Inc. La Jolla, CA, USA) was used to calculate the 
significance of the differences between groups using ANOVA followed by Tukey’s post-hoc analysis. 
Statistical significance was assumed at p < 0.05. 
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